BREAKING NEWS: National healthcare organizations urge Governors and Insurance Commissioners throughout the country to support broad coverage and payment of telemedicine services even after the COVID-19 pandemic ends. Read the letters to the Governors and the Insurance Commissioners here.
The Mississippi Society of Oncology was formed in 1991 for the purpose ofpromoting the highest professional standards of oncology in Mississippi, to study, research and exchange information, experiences and ideas leading to improvement in oncology and promote educational opportunities.
In addition, the MOS is committed to support the search for more effective treatments of malignant diseases, work with other organizations and societies that have concerns with cancer care, and disseminate information regarding regulatory developments affecting members.
And finally the MOS acts as a resource for insurers regarding the standard of care in oncology and represents the practice of oncology and hematology in the State of Mississippi.
MOS is happy to have partnered with NCODA to present their most recent webinars. You can watch all five parts of the COVID-19 series and a special ASCO/NCODA webinar on Patient-Centered Standards for Medically Integrated Dispensing by clicking HERE.
CORONAVIRUS INFORMATION FROM THE CDC
CDC is working across the Department of Health and Human Services and across the U.S. government in the public health response to COVID-19.
Please see links below for additional information:
IMPORTANT INFORMATION FOR ALL PROVIDERS FROM THE AMERICAN MEDICAL ASSOCIATION
As of January 1, 2021, there will be significant changes to the office and outpatient Evaluation and Management (E&M) services (CPT ® codes 99202-99215) for both new and established patients. Find out more
October 13, 2020 - The Latest Circuit Court Ruling on 340B Program Effect on Practices, Find out more
October 8, 2020 - On October 2, after consultation with public health officials, Department of Health and Human Services (HHS) Secretary Alex Azar, pursuant to the authority vested in him under section 319 of the Public Health Service Act, renewed the public health emergency effective October 23, 2020.
October 6, 2020 - Supreme Court scrutinizes Arkansas law that regulates PBM payments to pharmacies, Find out more
September 29, 2020 - Insurers Move to Stop Waiving Telehealth Copays - Find out more
September 18, 2020 - CMS Finalizes Radiation Oncology Model - Find out more
September 16, 2020 - AACR Releases Its Inaugural Cancer Disparities Report - Find out more
September 1, 2020 - CMS Quietly Resumes Practice Audits, Find out more
RxVantage recently shared a panel discussion of oncology experts from around the country who have exhibited impressive leadership amid COVID-19. These executives met via video conference to share experiences, discuss strategies that have worked (as well as those that have not), and their plans for moving forward. Click below to view each presentation:
On October 21, 2020, the Centers for Medicare & Medicaid Services (CMS) announced plans to delay the start date of the Radiation Oncology (RO) model until July 1, 2021. The change comes following stakeholder concerns—the Association for Clinical Oncology (ASCO) among them—about the challenges of implementing the model by the initial start date, January 1, 2021, during the COVID-19 pandemic.
The American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as, how COVID-19 is impacting the delivery of cancer care and patient outcomes. ASCO will deliver periodic reports with key findings so that the oncology community has real-time information to help inform treatment approaches for patients with cancer who have a confirmed COVID-19 infection. The reports will allow practices to easily and confidentially share information on COVID-19 infections among their patients.
Click HERE to view the slide presentation from the webinar.
CMS Finalizes FY 2021 Inpatient Rule On September 2, the Centers for Medicare and Medicaid Services (CMS) issued the FY 2021 Inpatient Prospective Payment System (IPPS) Final Rule. ASH submitted comments in July on the proposed rule. The Society is pleased that many of the provisions ASH supported have been finalized, including the creation of a new Medicare Severity Diagnosis Related Group (MS-DRG) for Chimeric Antigen Receptor (CAR) T-cell Immunotherapy, now the highest weighted MS-DRG with an unadjusted national base payment of around $240,000. CMS also finalized its proposal to exclude clinical trial cases from the calculation of the weight of the new MS-DRG in order to account for the cost differentiation between clinical trial and non-clinical trial cases. CMS’s final ruling on CAR-T reimbursement is a major advocacy win for ASH!
ASH Diversity, Equity, and Inclusion Efforts Help ASH eliminate inequities in hematology by getting involved with our diversity, equity, and inclusion (DEI) efforts. ASH has created an online library related to its programs in Diversity, Equity, and Inclusion, which includes a growing archive of stories from diverse voices in hematology.
NEW ASH Virtual Listening Sessions on Diversity, Equity, and Inclusion Coming soon: The ASH Virtual Listening Sessions on Diversity, Equity, and Inclusion will explore issues facing those from backgrounds traditionally disadvantaged in medicine, as well as DEI opportunities in the hematology community. ASH is currently seeking participants willing to share their thoughts and experiences on DEI issues related to race, ethnicity, gender, ability, and/or sexual orientation for the first set of listening sessions. ASH members interested in participating in the listening sessions are encouraged to sign up soon as we anticipate significant interest.